ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Efficacy of radiotherapy in stabilization of oligoprogressive lesions of malignant melanoma treated with immunotherapy.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to evaluate the effectiveness of radiotherapy (RT) in stabilizing oligoprogressive disease (OPD) in melanoma patients undergoing immunotherapy. We hypothesize that RT's efficacy in disease stabilization is influenced by factors such as dose, fractionation, metastatic burden, and the timing of OPD onset relative to immunotherapy initiation. Materials and methods: A retrospective observational study was conducted at two Czech university hospitals. Inclusion criteria encompassed metastatic melanoma patients undergoing immunotherapy with checkpoint inhibitors who developed OPD between January 2018 and May 2023. Exclusion criteria included central nervous system (CNS) involvement, discontinuation of systemic therapy during or after RT, and treatments other than immune checkpoint inhibitors. Patients were stratified based on RT initiation timing (< 6 months or > 6 months from immunotherapy start) to assess primary and acquired resistance. 34 patients were included, with RT administered for extracranial OPD. Among these, local control was achieved in 21 patients. Results: Higher doses of RT [> 40 Gy the equivalent dose in 2 Gy fractions (EQD2)] correlated with improved local control. Patients with fewer than five irradiated lesions experienced better progression-free survival (PFS) and overall survival (OS), however, the difference did not reach statistical significance. Multivariate analysis revealed that patients who received RT after > 6 months since initiation of immune checkpoint inhibitor (ICI) had significantly longer PFS. This study suggests, that RT is a viable option for stabilizing OPD in melanoma patients treated with immunotherapy, especially when administered later in the treatment course. Conclusions: Improved OS and PFS outcomes suggest that delayed OPD may indicate acquired resistance, which benefits from RT. Future studies should refine RT parameters and patient selection criteria to optimize clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.